News | July 13, 2012

Chemo Plus Radiation Significantly Improves Survival in Some Anaplastic Oligodendroglioma Brain Tumor Patients

July 13, 2012 — The long-term results of RTOG 9402, a randomized phase III trial evaluating the overall survival of patients with oligodendroglioma brain tumors who received either chemotherapy plus radiation therapy (Arm 1) or radiation therapy alone (Arm 2), was reported at the 2012 American Society of Clinical Oncology (ASCO) Annual Meeting, held June 1-5 in Chicago. At a median follow-up of 11.3 years, the study results reveal that patients whose tumor lacked both the 1p and 19q chromosomes (co-deleted tumors) lived twice as long when treated with chemotherapy immediately followed by radiation therapy, than when treated with radiation therapy alone.

“The association between improved outcome for patients who lack the 1p and 19q chromosomes and were treated with PCV chemotherapy [procarbazine, lumustine (CCNU) and vincristine] and radiation therapy has significant implication for patients with anaplastic oligodendrogliomas. We now have evidence that the chromosomal structure of 1p and 19q co-deletion can be used as a marker to determine which patients will benefit from combined chemotherapy and radiation therapy,” said J. Gregory Cairncross, M.D., principal investigator of the trial, professor and head of the department of clinical neurosciences at the University of Calgary, Alberta, Canada.

The RTOG 9402 trial was one of the first to determine that the genetic makeup of a brain tumor determines the magnitude of treatment effectiveness. “The results of this trial are a testament to the importance of the genetic makeup of a brain tumor in predicting how it will respond to treatment, regardless of microscopic appearance,” said Cairncross. The trial’s long-term results were substantiated by the similar results of a European Organization for Research and Treatment of Cancer-conducted trial (EORTC 26081-22086) that was also presented at the ASCO meeting.” 

Conducted with four other National Cancer Institute (NCI)-supported cooperative groups between 1994 and 2002, the study enrolled 291 study participants. No significant difference in median survival time (MST) was found between the two treatment arms in participants whose tumors contained only one deletion (1p or 19q) or had no deletions. Among participants with 1p/19q co-deletion, however, MST was doubled in participants in the chemotherapy and radiation treatment arm as opposed to the radiation-only arm (14.7 years MST vs. 7.3 MST).

“These are exciting and practice-changing results,” said Walter J. Curran, Jr., M.D., RTOG group chair and executive director of the Winship Cancer Institute of Emory University in Atlanta. “The announcement of the RTOG 9402 long-term results provided important information that prompted the closure of a trial led by North Central Clinical Trials Group (RTOG 1071). Better understanding of the molecular characteristics of this co-deleted tumor type provided background knowledge for the development of clinical trials evaluating new treatment regimens for patients with the 1p and 19q chromosome co-deletion, including one led by the EORTC (RTOG 0834).”

For more information: www.rtog.org

Related Content

Immune Inflammatory Levels Linked to Disease-Free Survival in Prostate Cancer
News | Prostate Cancer | November 19, 2018
Data from a validation study of a high-risk prostate cancer trial suggests that higher levels of pretreatment...
Merit Medical Completes Acquisition of Cianna Medical
News | Women's Health | November 14, 2018
Disposable device manufacturer Merit Medical Systems Inc. announced the closing of a definitive merger agreement to...
Videos | ASTRO | November 08, 2018
ITN Editor Dave Fornell took a tour of some of the most innovative technologies on display on the expo floor at the 
The Fujifilm FCT Embrace CT System displayed for the first time at ASTRO 2018.
360 Photos | 360 View Photos | November 07, 2018
Fujifilm's first FDA-cleared compu...
This is the Siemens Magnetom Sola RT edition 1.5T MRI system optimized for radiation therapy displayed for the first time since gaining FDA clearance in 2018. It was displayed at the American Society for Radiotherapy and Oncology (ASTRO) 2018 annual meeting. Read more about this system at ASTRO 2018. #ASTRO18 #ASTRO2018
360 Photos | 360 View Photos | November 07, 2018
This is the Siemens Magnetom Sola RT edition 1.5T MRI system optimized for...
GE Healthcare Discovery RF Gen 2 system displayed at ASTRO 2018. It is a dedicated computed tomography (CT) scanner for radiation oncology
360 Photos | 360 View Photos | November 07, 2018
This is the GE Healthcare Discovery RF Gen 2 system displayed at the ...
Proton Therapy for Pediatric Brain Tumors Has Favorable Cognitive Outcomes
News | Proton Therapy | November 06, 2018
Proton therapy treatment for pediatric brain tumor patients is associated with better neurocognitive outcomes compared...
Videos | Radiation Oncology | November 06, 2018
Genomics can be used to assess a patient's radiosensitivity, which can be used to increase or decrease the radiation